A Phase 4 interventional study of Oxycodone Hydrochloride and Morphine Sulphate in Cancer Pain, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing oxycodone in Cancer Pain — 1 open to participants now, 1 under way, none of them phase 3. Oxycodone · Cancer Pain.
Among the 10 studies testing oxycodone in Cancer Pain, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 7 in phase 4, and was the 7th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →1 of the 10 studies testing oxycodone in Cancer Pain is open now. Recruiting first, the newest first:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 44 Cancer Pain studies recruiting now, 32 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 63 across 236 interventional studies indexed under Cancer Pain.
Median enrollment 153 across the 10 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 7 most frequent:
This study is registered under Mundipharma Korea Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma Korea Ltd is the lead sponsor of 16 studies on the registry; none are open to participants now.
11 studies in Cancer Pain by Mundipharma: 1 open now, 1 under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 11 studies in Cancer Pain by Mundipharma, this one is the only one that started in 2015, is one of 5 in phase 4, and was the 5th registered.
Mundipharma’s Cancer Pain studies by the year they started, since 2008.
1 of the studies testing oxycodone in Cancer Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT052650523D Medicines3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing oxycodone in Cancer Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mundipharma’s 11 in Cancer Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.
5days, Multi-centers, Randomization, Open label, Parallel, Active Comparator, Phase 4 Study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
Drug: Oxycodone Hydrochloride
Brand name: BC Morphine sulfate Generic name: Morphine sulfate
Drug: Morphine Sulphate
Oxycodone injection
Also known as: Oxynorm
Morphine sulphate injection
Also known as: BC morphine
Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5.
For the pain assessment value for efficacy assessment, Subjects perform pain grading through Numeric rating score(NRS) from 1 to 10 for the mean pain intensity over the past 7 days at Screening, and mean pain intensity over the past 24 hours at Baseline (Day 0), Day 1, Day 2, Day 3, Day 4, Day 5. Verbal measurement can be conducted by subjects without using visual data. '0' indicates 'no pain', and as the number increases, the pain gets more severe, and '10' indicates the worst pain.
Time frame: 5 days
Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration
The dose of the study drugs intravenously administered was checked and recorded every day. The information on the dose administered from baseline to each assessment time point was collected based on records on the chart, and in the event of dose change/end of treatment, pertinent date and time, and dose were recorded accurately on the chart. ‡ Total administered dose of the study drugs (mg)= IV infusion (mg/hr) \* \[(End date - start date) \* 24 + (end time - start time)\] + bolus injection (mg)
Time frame: 5 days
Patient's Overall Satisfaction With Each Continuous Infusion on Day 5 After Randomization
The subjects made an assessment of overall treatment satisfaction regarding pain using the PGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse) after baseline and at the end of the study (Day 5).
Time frame: 5 days
Investigator's Overall Satisfaction With IV Infusion on 5 Days After Randomization
The investigators made an assessment using the CGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse).
Time frame: 5 days
| Milestone | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| Started | 34 | 32 |
| Safety analysis set | 34 | 32 |
| Fas set | 33 | 32 |
| Per protocol set | 28 | 29 |
| Completed | 32 | 31 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
For the pain assessment value for efficacy assessment, Subjects perform pain grading through Numeric rating score(NRS) from 1 to 10 for the mean pain intensity over the past 7 days at Screening, and mean pain intensity over the past 24 hours at Baseline (Day 0), Day 1, Day 2, Day 3, Day 4, Day 5. Verbal measurement can be conducted by subjects without using visual data. '0' indicates 'no pain', and as the number increases, the pain gets more severe, and '10' indicates the worst pain.
| units on a scale | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| Change in the Mean Pain Score(NRS) From Baseline(Day 0) to Day 5. | -3.52 ± 2.17 | -3.13 ± 1.84 |
The dose of the study drugs intravenously administered was checked and recorded every day. The information on the dose administered from baseline to each assessment time point was collected based on records on the chart, and in the event of dose change/end of treatment, pertinent date and time, and dose were recorded accurately on the chart. ‡ Total administered dose of the study drugs (mg)= IV infusion (mg/hr) \* \[(End date - start date) \* 24 + (end time - start time)\] + bolus injection (mg)
| mg | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| Total Dose of IV(IV Infusion+Bolus Injection) Study Drug Administered During the Treatment Duration | 226.80 ± 110.44 | 226.64 ± 135.13 |
The subjects made an assessment of overall treatment satisfaction regarding pain using the PGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse) after baseline and at the end of the study (Day 5).
| Participants | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| 1:Very much improved | 9 | 8 |
| 2: Much Improved | 10 | 10 |
| 3: Minimally improved | 12 | 12 |
| 4: No change | 1 | 1 |
| 5: Minimally worse | 0 | 0 |
| 6: Much worse | 0 | 0 |
| 7: Very much worse | 0 | 0 |
The investigators made an assessment using the CGI-C on a 7-point scale (1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse).
| Participants | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| 1: Very much improved | 10 | 9 |
| 2: Much improved | 16 | 15 |
| 3: Minimal improved | 5 | 6 |
| 4. No change | 1 | 1 |
| 5. Minimally worse | 0 | 0 |
| 6. Much worse | 0 | 0 |
| 7. Very much worse | 0 | 0 |
Collected over 5 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxycodone Hydrochloride | 0/34 (0%) | 3/34 (8.8%) | 14/34 (41.2%) |
| Morphine Sulphate | 0/32 (0%) | 2/32 (6.3%) | 11/32 (34.4%) |
| Event | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/34 | 1/32 |
| NeutropeniaBlood and lymphatic system disorders | 1/34 | 1/32 |
| PyrexiaGeneral disorders | 1/34 | 0/32 |
| Platelet count decreasedInvestigations | 1/34 | 0/32 |
| Event | Oxycodone Hydrochloride | Morphine Sulphate |
|---|---|---|
| ConstipationGastrointestinal disorders | 7/34 | 3/32 |
| NauseaGastrointestinal disorders | 4/34 | 5/32 |
| DizzinessNervous system disorders | 2/34 | 3/32 |
| SomnolenceNervous system disorders | 3/34 | 1/32 |
| VomitingGastrointestinal disorders | 0/34 | 1/32 |
| AstheniaGeneral disorders | 0/34 | 1/32 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 0/34 | 1/32 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/34 | 1/32 |
| DysuriaRenal and urinary disorders | 0/34 | 1/32 |
| DyspepsiaGastrointestinal disorders | 1/34 | 0/32 |
Demographic data was analysed FAS set.
| Age, Customized(participants) | Oxycodone Hydrochloride | Morphine Sulphate | Total |
|---|---|---|---|
| <39 years | 0 | 2 | 2 |
| 40-49 years | 1 | 2 | 3 |
| 50-59 years | 5 | 6 | 11 |
| 60-69 years | 27 | 22 | 49 |
| Sex: Female, Male(Participants) | Oxycodone Hydrochloride | Morphine Sulphate | Total |
|---|---|---|---|
| Female | 12 | 10 | 22 |
| Male | 21 | 22 | 43 |
| Region of Enrollment(participants) | Oxycodone Hydrochloride | Morphine Sulphate | Total |
|---|---|---|---|
| Korea, Republic of | 33 | 32 | 65 |
Plan to share: No
The record gives a start of Nov 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone